50
Participants
Start Date
July 22, 2021
Primary Completion Date
June 5, 2024
Study Completion Date
June 5, 2024
Pepinemab
Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Placebo
Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Columbia University Irving Medical Center, New York
Neurological Associates of Albany, Albany
Dent Neurological Associates, Amherst
University of Rochester Medical Center, Rochester
Georgetown University, Washington D.C.
Re-Cognition Health, Fairfax
Brain Matters Research, Delray Beach
JEM Research Institute, Lake Worth
Premiere Research Institute of Palm Beach, Neurology, Palm Beach
Neuropsychiatric Research Center of Southwest Florida, Fort Myers
Brain Matters Research, Stuart
Indiana University School of Medicine, Indianapolis
University of Kansas Medical Center, Fairway
Pacific Research Network, Inc, San Diego
Alzheimer's Drug Discovery Foundation
OTHER
Alzheimer's Association
OTHER
Vaccinex Inc.
INDUSTRY